Dubai, UAE – May 12, 2026 — Kings Research today announced its new report, “Global Positron Emission Tomography Market: Size, Share, Trends & Forecast 2025–2032.” The report provides comprehensive insights into PET systems across segments such as product type, modality, radiotracer/isotope, application, and end-user, along with regional dynamics and competitive strategies. It is designed to support healthcare providers, diagnostic centers, radiopharmaceutical companies, and medical imaging stakeholders in strategic decision-making.
According to Kings Research, the global positron emission tomography market was valued at USD 1,090.7 million in 2024, is projected to grow to USD 1,130.0 million in 2025, and is expected to reach USD 1,447.4 million by 2032, exhibiting a CAGR of 3.61% during the forecast period.
Positron emission tomography (PET) is a nuclear medicine imaging technique that uses radiotracers to visualize metabolic processes in the body. It is widely used in oncology, cardiology, and neurology for early disease detection, staging, and treatment monitoring. PET is often combined with CT or MRI (PET-CT, PET-MRI) to provide both functional and anatomical insights, significantly improving diagnostic accuracy and patient outcomes.
Kings Research underscored some of the major trends influencing the positron emission tomography market. These include:
● Rising Global Cancer Burden
The increasing incidence of cancer is a major driver for PET imaging adoption. According to the World Health Organization (WHO), cancer accounted for nearly 10 million deaths globally in 2022, making it a leading cause of death worldwide. PET scans play a critical role in tumor detection, staging, and therapy monitoring, thereby driving demand across oncology diagnostics.
● Growing Burden of Neurological Disorders
Neurological diseases are increasing rapidly, boosting the need for advanced imaging. The WHO estimates that over 1 in 3 people are affected by neurological conditions, highlighting the need for early and accurate diagnosis. PET imaging is increasingly used in detecting Alzheimer’s disease and other neurodegenerative disorders.
● Expansion of Nuclear Medicine Infrastructure
Investments in nuclear medicine facilities and imaging infrastructure are accelerating globally. According to the International Atomic Energy Agency (IAEA), more than 40 million nuclear medicine procedures are performed annually worldwide, reflecting the growing demand for advanced imaging technologies such as PET. This expansion is improving access to advanced diagnostics in both developed and emerging economies.
● Rising Cardiovascular Disease Burden
Cardiovascular diseases continue to drive demand for diagnostic imaging. An estimated 19.8 million people died from cardiovascular diseases in 2022, representing approximately 32% of all global deaths. PET imaging is increasingly used for myocardial perfusion imaging and cardiac viability assessment.
For hospital administrators, radiology heads, nuclear medicine specialists, and diagnostic imaging leaders, positron emission tomography solutions deliver critical clinical and operational advantages:
- Enhanced Diagnostic Accuracy: PET imaging enables early and precise disease detection, improving clinical outcomes.
- Growing Oncology Applications: Increasing cancer prevalence strengthens long-term demand for PET systems and radiotracers.
- Integration with Hybrid Imaging: PET-CT and PET-MRI technologies provide comprehensive diagnostic insights.
- Radiotracer Innovation: Advancements in isotopes improve imaging specificity and expand clinical applications.
- Operational Efficiency: Automated imaging workflows enhance throughput and reduce diagnostic delays.
- Expansion Opportunities: Emerging markets offer strong growth potential due to improving healthcare infrastructure.
Regional Outlook
- North America: North America dominates the positron emission tomography market, supported by advanced healthcare infrastructure, high adoption of hybrid imaging systems, and strong presence of key market players. Favorable reimbursement frameworks and early adoption of innovative radiotracers further drive regional growth.
- Asia-Pacific: Asia-Pacific is the fastest-growing region, driven by rising healthcare investments, increasing cancer prevalence, and expanding diagnostic capabilities. Countries such as China and India are witnessing rapid growth in nuclear medicine infrastructure and imaging accessibility.
Competitive Landscape
Kings Research identifies the following as leading players in the positron emission tomography market: GE HealthCare, Siemens Healthineers AG, Philips, Canon Medical Systems Corporation, United Imaging Healthcare Co. Ltd., Mediso Ltd., CMR Naviscan Corporation, Bruker Corporation, Positron Corporation, Agfa HealthCare NV, Segami Corporation, SOFIE Biosciences, Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, and Neusoft Medical Systems Co. Ltd.
These companies are focusing on developing advanced PET systems, hybrid imaging technologies, and novel radiotracers. Strategic collaborations with hospitals, research institutions, and radiopharmaceutical companies are enabling them to expand their product portfolios and strengthen their market presence.
To request a free sample or to access the full “Global Positron Emission Tomography Market: Size, Share, Trends & Forecast 2025–2032” report, please visit:
https://www.kingsresearch.com/report/positron-emission-tomography-market-3035
About Kings Research
Kings Research is a global research and consulting firm that helps organizations navigate emerging markets, evaluate opportunities, and make data-driven decisions.
All market data are sourced from Kings Research proprietary analysis, validated against credible government publications and peer-reviewed research papers. Examples cited include: World Health Organization (WHO), International Atomic Energy Agency (IAEA), U.S. National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and other peer-reviewed medical and public health research sources.